S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 23
Citations - 2115
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Chronic myelogenous leukemia & Imatinib mesylate. The author has an hindex of 19, co-authored 23 publications receiving 2000 citations. Previous affiliations of Stefan Faderl include University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Hagop Kantarjian,Susan O'Brien,Jorge Cortes,Francis Giles,Stefan Faderl,Elias Jabbour,Guillermo Garcia-Manero,William Wierda,R N Sherry Pierce,Jianqin Shan,Elihu Estey +10 more
TL;DR: The aim was to develop prognostic models for complete response (CR), induction (8‐week) mortality, and survival rates in elderly AML, which would be used to advise oncologists and patients of expectations with standard AML type therapy, and to establish baseline therapy results against which novel strategies would be evaluated.
Journal ArticleDOI
The biology and therapy of adult acute lymphoblastic leukemia.
TL;DR: The recognition of several subgroups of ALL and the institution of risk‐adapted therapies and new therapies are emerging based on the definition of specific cytogenetic‐molecular abnormalities.
Journal ArticleDOI
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia.
Jorge Cortes,Deborah Thomas,Adan Rios,Charles Koller,Susan O'Brien,Sima Jeha,Stefan Faderl,Hagop Kantarjian +7 more
TL;DR: The authors investigated the feasibility and efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper‐CVAD), a dose‐intensive chemotherapy regimen, in patients with AIDS‐associated Burkitt lymphoma/leukemia, as well as the possible impact of highly active antiretroviral therapy (HAART) in these patients.
Journal ArticleDOI
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Thomas B. Sneed,Hagop Kantarjian,Moshe Talpaz,Susan O'Brien,R N Mary Beth Rios,B. Nebiyou Bekele,Xian Zhou,R N Debra Resta,William G. Wierda,Stefan Faderl,Francis Giles,Jorge E. Cortes +11 more
TL;DR: During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression ≥ Grade 3, requiring interruption of therapy and/or dose reductions.
Journal ArticleDOI
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders†
Jorge Cortes,Francis Giles,Susan O'Brien,Deborah Thomas,Maher Albitar,Mary Beth Rios,Moshe Talpaz,Guillermo Garcia-Manero,Stefan Faderl,Laurie Letvak,August Salvado,Hagop Kantarjian +11 more
TL;DR: Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R) that is implicated in the pathogenesis of myeloproliferative disorders (MPD).